Objective: Intra-articular (IA) corticosteroids relieve osteoarthritis (OA) pain, but rapid absorption into systemic circulation may limit efficacy and produce untoward effects. We compared the pharmacokinetics (PK) of IA triamcinolone acetonide (TA) delivered as an extended-release, microsphere-based formulation (FX006) vs a crystalline suspension (TAcs) in knee OA patients.
Introduction
Osteoarthritis (OA) is increasingly recognized as a serious condition 1 . Specifically, people with OA have an increased causespecific mortality risk attributable to cardiovascular and gastrointestinal disorders 2 , and those with symptomatic radiographic knee OA have been shown to have 23% higher risk of dying prematurely than individuals without OA 1 . Possible explanations for the excess mortality include reduced physical activity; comorbid conditions; and adverse effects of OA medications, particularly non-steroidal anti-inflammatory drugs and opioids. There remains a need for safe therapies that effectively treat the symptoms and functional consequences of OA. Inflammation plays a key role in OA pathogenesis. Serial magnetic resonance imaging and histopathological analysis of synovial tissues show synovitis is associated with more severe joint pain and cartilage loss, and decreased mobility 3e11 . Thus, synovitis is increasingly recognized as an important treatment target 12e16 .
Intra-articular (IA) corticosteroids such as triamcinolone acetonide crystalline suspension (TAcs) are a mainstay in short-term management of OA pain 17e21
. Pain relief associated with IA corticosteroids is consistent with their known anti-inflammatory actions, particularly the regulation of inflammatory transcription factors and post-transcriptional pathways 22e24 . The inflamed synovium is the likely site of IA corticosteroid activity 25e28 . Synovial tissue volume not only shrinks in patients with knee OA post-steroid therapy, but also rebounds when pain relapses 29 . However, pain relief associated with IA corticosteroids diminishes in the weeks following injection 18,30e32 , most likely due to efflux of drug from the joint beginning within hours of injection 33 . This rapid systemic absorption from the joint not only limits the duration of analgesic and anti-inflammatory effects of IA corticosteroids, but also can lead to cardiovascular and metabolic systemic effects 34 . Drug development efforts aimed at limiting the rapid efflux and extending the duration of IA corticosteroid presence may enhance the magnitude and duration of analgesic effect and mitigate systemic effects. FX006 is a novel, extended-release, poly (lactic-co-glycolic acid) (PLGA) microsphere-based TA formulation designed to prolong the drug's residence time in the synovial tissues and fluid following IA injection. In vitro experiments show that the crystals of TA from the TAcs formulation completely dissolve in <2 h; in the same time period and under the same conditions, <1% of the embedded TA from the FX006 formulation is released from the PLGA matrix (Sponsor data on file). Previously, a single, 3-mL, IA injection of FX006 substantially increased the duration of TA joint residency, markedly reduced systemic exposure, and demonstrated both prolonged and increased analgesia relative to TAcs 40 mg in patients with knee OA 35e37 . Subsequently, the FX006 diluent reconstitution volume was increased from 3 mL to 5 mL to facilitate microsphere dispersion. The current study was conducted to characterize the synovial fluid (SF) and plasma TA PK profiles of FX006 for the 5-mL injection volume and to compare the SF and plasma TA PK profiles with those of TAcs (1-mL injection volume), one of the most common IA knee OA therapies. 38 , with symptoms for !6 months prior to screening and patient-reported index-knee pain for !15 days of the preceding month. Patients with arthroscopic/open surgery of the index knee (i.e., most painful in patients with bilateral disease) within 12 months of screening or planned/anticipated index-knee surgery during the study were excluded. Additional exclusion criteria included uncontrolled diabetes (hemoglobin A1c >7.5%) and treatment with IA corticosteroids in any joint <6 months; IA hyaluronic acid in the index knee <6 months; intravenous or intramuscular corticosteroids <3 months; oral corticosteroids <1 month; and/or inhaled, intranasal or topical corticosteroids <2 weeks prior to screening. These same treatments, and any IA intervention (e.g., non-protocol-specified aspiration) of the index knee, were prohibited during study participation. Because this study did not evaluate efficacy, there was no minimum painintensity criterion at entry, and analgesic medications (e.g., nonsteroidal anti-inflammatory drugs and opiates) were allowed.
Patients and methods

Ethical considerations
Study interventions
FX006 powder was reconstituted in diluent containing an isotonic, sterile, aqueous sodium chloride solution (0.9% weight/ weight [w/w]), carboxymethylcellulose (0.5% w/w) plus polysorbate-80 (0.1% w/w) and administered as a 5-mL injection. FX006 dosedelivery studies determined that this resulted in administration of 32 mg of TA. Commercially available TAcs 40 mg (Kenalog ® -40; Bristol-Myers Squibb Company, Princeton, NJ, USA) was administered as a 1-mL injection, allowing comparisons between FX006 and a current standard of care. Patients were to avoid strenuous activities or prolonged weight-bearing activities for 24e48 h post-IA injection and maintain a stable level of physical activity throughout the study.
Study assessments
To optimize needle placement and volume of SF collected, index knee aspirations were performed with ultrasound guidance at baseline and Weeks 1, 6, 12, 16, SF and plasma TA concentrations were both measured using validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays. For SF, frozen samples were thawed at room temperature, followed by addition of internal standard working/ phosphate-buffered solutions. Following mixing and a liquideliquid extraction (methyl tert-butyl ether and hexanes), the samples were centrifuged. Using the Janus liquid handling system (PerkinElmer, Shelton, CT, USA), a portion of each sample's organic phase was transferred into a 96-well plate. The organic phase was evaporated, and samples were reconstituted using a methanol/ water mixture prior to injection into a LC-MS/MS (ACE C18, 30 mm Â 4.6 mm, 3-mm particle size column, water/methanol mobile phase, ionization in positive mode with a heated nebulizer). Masses monitored for the analyte in SF were 435/415 and 435/397 and for the internal standard were 442/422 and 422/ 404. The TA quantification process employed a 2.5Â overall dilution factor.
The lower limits of quantification (LLOQs) differed between the two matrices, i.e., 50.0 pg/mL for SF and 10.0 pg/mL for plasma, with the SF matrix exhibiting less assay sensitivity due to more interference from the SF components detected at the analyte's retention time relative to that observed in plasma. The LLOQ of 50 pg/mL represents 1e2% of the expected maximum concentration (C max ) in SF and is judged sufficient to characterize the PK profile of the analyte in SF.
Safety was assessed through monitoring of adverse events (AEs). Index knees were assessed for tenderness, heat/redness, swelling, effusion, and Baker's cyst. Clinically significant findings during screening/baseline were reported as part of the patient's medical history, while new clinically significant findings or worsened postbaseline findings were recorded as AEs.
Data analysis
The SF and plasma TA concentrations were assessed using noncompartmental analysis (Phoenix 64
models on the SF and Plasma Drug Concentration Populations, respectively ( Fig. 1 ). Sparse sampling methodology following Day 1 was implemented across the plasma concentration profile to capture population-based data at the end of the sampling profile. All plasma concentration values were set to 0 for pre-dose (time 0) and post-baseline samples that were assayed as below the LLOQ (BLOQ); geometric mean (GM) data are presented. Due to the small number of patients contributing SF samples at each post-dose time point, we also employed sparse sampling modeling, with each patient contributing only a pre-dose sample and one post-dose sample. For SF samples, pre-dose and post-baseline concentrations BLOQ were set to 0. To obtain a reasonable estimate of the GM SF values, a scaler value of 1 was added to each observed concentration value; thus, values BLOQ for the computation of GM appear in the descriptive SF summaries as a value of 1. TA concentration data were presented by time point pooled across FX006 cohorts and separately for the TAcs cohort. The PK non-compartmental analysis models were completed using Phoenix ® 64 WinNonlin ® (Version 6.4) using the PK Population ( Fig. 1) , and graphical displays of PK analyses and concentration information were completed with Sigma Plot (Version 13.0). PK parameters derived from plasma TA concentrations were either observed or estimated by WinNonlin ® (Version 6.4 No formal sample size computations were completed for this descriptive study. A minimum of 10 patients/cohort was planned to provide !6 patients/cohort providing SF TA concentration data for estimation of GM values to within approximately 3-fold with 95% confidence. The sample size of 10 patients/cohort also was considered sufficient to characterize the FX006 PK profile using a 5-mL injection volume.
Results
Patient disposition
The study was conducted from 11/30/2015 through 9/8/2016 at four United States study centers. Eighty-one enrolled patients received a single IA injection of FX006 (N ¼ 63) or TAcs (N ¼ 18) on Day 1. Patients sequentially enrolled into FX006 SF collection cohorts included: 13 for the Week 1; 20 for the Week 6; and 10 each for the Weeks 12, 16, and 20 cohorts (Table I) . Three patients discontinued the study early (two FX006 lost to follow-up (LTFU), one TAcs protocol non-compliant).
Sixty of 63 (95.2%) FX006 and 18/18 (100%) TAcs patients were included in the Plasma Drug Concentration and PK Populations. Twenty-nine of 63 (46.0%) FX006 and eight of 18 (44.4%) TAcs patients were included in the SF Drug Concentration Population. Not all cohorts achieved !6 patients providing SF samples at later visits, primarily due to <0.1 mL of SF being aspirated at the final sampling time point, yielding 2e9 patients/cohort and 37/81 (45.7%) patients across all cohorts providing SF samples. Details of the Safety, Plasma Drug Concentration, SF Drug Concentration, and PK populations are provided in Fig. 1 .
Baseline characteristics
Among patients treated across study cohorts (Safety Population), the 36 (44.4%) men and 45 (55.6%) women had a mean age of 60 years, mean BMI ranging from 30 to 32 kg/m 2 across cohorts, mean time since primary OA diagnosis of almost 8 years, and a mean of 29 days of index-knee pain within the month preceding screening. As expected, based on lack of randomization and relatively small cohort sample sizes, baseline characteristics varied across cohorts (Table I) .
FX006 SF and plasma TA concentrations
Following a single IA injection of FX006, the GM SF TA C max of 231,321.3 pg/mL was reached at a median time to maximum concentration (t max ) of 168.0 h (i.e., Week 1). Thereafter, SF TA concentrations declined, with GMs of 3590.0 pg/mL at Week 6 and 290.6 pg/mL at Week 12. After Week 12, TA was BLOQ in the small number of SF samples obtained (Fig. 2) .
FX006-TA demonstrated some systemic absorption, with a plateau in plasma TA concentrations through Hour 24 followed by slow elimination from the systemic circulation (Fig. 3) . The GM C max (966.7 pg/mL) was reached at a median t max of 7.0 h. The median t ½ was 347.0 h, GM MRT was 453.7 h, and GM clearance was slow (0.0001 mL/h/kg). The GM last measurable concentration (106.4 pg/ mL) was observed at a median time to last measurable concentration (t last ) of 1008.0 h (approximately Week 6) (Table II) .
TAcs SF and plasma TA concentrations
Following a single IA injection of TAcs, TA SF concentrations were BLOQ at Week 6 (Fig. 2) . Of the eight patients who contributed samples at Week 6, only two had measurable SF TA concentrations at this time point, yielding a GM SF TA concentration of 7.7 pg/mL, notably lower than that seen with FX006 at Week 6 (3590.0 pg/mL).
Systemic TA absorption was relatively rapid post-TAcs injection, with GM plasma TA concentrations determined for each sampling time point peaking at 4 h (9628.8 pg/mL) and declining to 4991.1 pg/mL at Hour 24 post-injection (Fig. 2) . The observed GM C max of 11,064.7 pg/mL was reached at a median t max of 6 h. The median t ½ (72.5 h) was shorter than that seen with FX006. GM MRT observed was 60.9 h, and GM AUC (0e6 weeks) was 3,082,834.8 h * pg/ mL, which was 6Â higher than that observed with FX006 (Table II) .
Safety
AEs were reported for 11.1% (7/63) of FX006-and 11.1% (2/18) of TAcs-treated patients. The only AEs reported by >1 patient were hypertension in two FX006-treated patients (both with a history of hypertension) and flushing in two TAcs-treated patients (considered to be related to the injection procedure in both patients). The vast majority of AEs were Grade-1 or 2 and assessed by the investigator to be unrelated to study drug. One Grade-4 pulmonary embolism occurred in an FX006-treated patient with a history of pulmonary embolism (serious AE considered unrelated to study drug, injection procedure, or index knee). The AEs considered related to study drug were a Grade-1 arthralgia and a Grade-2 patellofemoral pain syndrome in FX006-treated patients and the Grade-1 flushing noted above in two TAcs-treated patients. The incidence of index-kneerelated AEs in the patients treated with FX006 was 3.2% (2/63). No patient died or discontinued due to an AE.
Discussion
Results of this Phase 2 open-label study indicate that microsphere-based extended-release delivery of TA via a single 5-mL IA injection of FX006 prolonged TA IA residency time, diminished peak TA plasma levels, and substantially reduced the systemic TA exposure relative to a single IA injection of a standard crystalline suspension of TA. Over the first week following IA FX006 injection, TA concentrations in the systemic circulation plateaued at low levels relative to values produced by TAcs, suggesting that TA remains in the SF and synovial tissues following injection, with slow absorption into systemic circulation. Prolonged joint residency is further supported by assessments of local TA concentrations in SF showing variable but quantifiable levels out to Week 12 post-injection, whereas those post-TAcs were either very low (two patients) or not quantifiable (six patients) at Week 6.
Synovial concentrations of TA e clinical implications
The differences in SF TA concentrations observed in this studydGMs of 3590.0 and 290.6 pg/mL at Week 6 and Week 12, respectively, for FX006 and 7.7 pg/mL at Week 6 for TAcsdlikely constitute the basis for pharmacologic differentiation and provide a rational hypothesis for between-treatment efficacy differences observed in Phase 2/3 trials 37, 39, 47 . For example, exploratory analyses from a Phase 3, multicenter, double-blind, 24- activity of corticosteroids is increased with prolonged delivery or targeting to inflamed synovial tissues as assessed histologically.
43,44
Systemic concentrations of TA e clinical implications
The plasma TA concentration profile associated with FX006 in this studyda GM of 759.5 pg/mL at 4 h post-injection that plateaued over the first 24 h, followed by a slow decline to~100 pg/mL through Week 20dindicates TA remains in the SF and tissues following IA injection, with corresponding slow elimination into systemic circulation (Fig. 3) . These data are consistent with the results from two prior studies in patients with knee OA that included plasma PK sampling after a single injection of the same dose of FX006; plasma TA concentration curves over time were similar across studies 36, 37 . Conversely, systemic TA absorption was rapid following IA injection of TAcs: plasma TA concentrations reached a GM C max of 11,064.7 pg/mL at a median t max of 6 h, and declined to 4991.1 pg/mL by 24 h. A similar plasma TA concentration profile following TAcs also was reported in a previous study in patients with knee OA, in which levels peaked at approximately 13,000 pg/mL on Day 1 and decreased in a log-linear manner to a value of approximately 100 pg/mL on Day 18 37 . The difference in systemic TA profiles resulting from IA FX006 compared with IA TAcs is underscored by the results from a post-hoc analysis used to demonstrate bioequivalence 45 , which confirmed significantly lower systemic TA exposure following FX006 relative to TAcs (Online Supplement, Table S1 ). While the total systemic exposure to TA from FX006 is substantially lower than that of TAcs, the duration of measureable levels of TA associated with FX006 is longer due to the extendedrelease mechanism of the PLGA microsphere. In a prior study, persistent low levels of systemic TA resulting from the same dose of FX006 were examined to determine whether or not they affected the function of the hypothalamic-pituitary-adrenal axis as measured by serum cortisol in patients with knee OA 35 . Through Week 6 post-injection, the cumulative cortisol suppression associated with FX006 was similar to that associated with TAcs 35 . As such, it is unlikely that IA administration of FX006 will compromise cortisol production or responses to stress throughout its duration of Results from a recent study of patients with knee OA and type-2 diabetes mellitus assessing the effects of FX006 and TAcs on blood glucose over 72 h post-injection showed that FX006 was associated with a statistically significant (P < 0.05, 2-sided) and clinically relevant reduction in the rise of blood glucose 46 . As such, the overall reduced systemic TA exposure associated with FX006, particularly the low peak concentrations, suggests that FX006 has the potential to confer an improved safety profile relative to TAcs; additional studies are needed.
Safety data e clinical implications
Safety data from the 63 FX006-treated and 18 TAcs-treated patients identified no new or unexpected safety concerns for either agent. These findings are consistent with those observed in larger Phase 2/3 clinical trials of FX006, in which a single IA FX006 injection demonstrated systemic and local safety profiles generally similar to placebo and TAcs, and no post-injection flares were observed. 37, 39, 47 Despite prolonged TA joint residence associated with microsphere delivery, index-knee related AEs were limited to two FX006-treated patients (Grade-1 arthralgia, Grade-2 patellofemoral pain syndrome). This lack of adverse local effect is not unexpected given that the FX006 PLGA matrix degrades to oligomeric poly-acid units, then to lactic and glycolic acids 48 , followed by elimination as carbon dioxide and water.
Study limitations
Results are limited by small sample sizes and acquisition of fewer-than-planned SF samples. Patients were not randomized, but were sequentially enrolled starting with FX006 and followed by TAcs treatment groups. Nonetheless, findings are generally consistent with SF and plasma PK evaluations conducted for the earlier FX006 3-mL formulation, which also showed that FX006 substantially reduced systemic exposure to, and prolonged IA residence of, TA relative to TAcs 35e37 . Specifically, in a previous assessment of SF TA concentrations, variable but quantifiable TA levels were observed through 16 weeks post-injection 37 . Additionally, FX006 (3-mL formulation) produced substantially lower peak plasma TA concentrations than TAcs when given at matched doses in a larger (N ¼ 228), double-blind, randomized, multicenter, Phase 2 trial in knee OA. 37 
Conclusions
These SF and plasma PK observations are consistent with slow release of TA into SF and tissues and blunted absorption into systemic circulation following a single IA injection of FX006 microspheres, yielding prolonged IA residency of TA relative to TAcs in patients with knee OA.
Author contributions
All authors made substantial contributions to study conception/ design (JL, JJ, JH, NB), data acquisition (HAA, PM, AJK, JL, JH, NB), PK modeling (JJ), or data analysis/interpretation (VBK, HAA, PM, AJK, JL, JJ, SK, NB); drafted the article or revised it critically for important intellectual content (VBK, HAA, PM, AJK, JL, JJ, SK, NB); and approved the final submitted version (VBK, HAA, PM, AJK, JL, JH, JJ, SK, NB). VBK (kraus004@duke.edu) and NB (nbodick@flexiontherapeutics. com) take responsibility for the integrity of the work as a whole, from inception to finished article.
Competing interests statement VB Kraus received consulting fees from Flexion Therapeutics, Inc. PG Conaghan has received compensation for consultancies from AbbVie, Bioiberica, Flexion Therapeutics, Inc., Infirst, and MerckSerono.
HA Aazami has reported no conflicts of interest. P Mehra has reported no conflicts of interest. AJ Kivitz has received consulting fees from AbbVie, Genentech, Janssen, Pfizer, and UCB.
J Lufkin, J Hauben, JR Johnson, and N Bodick are/were employed by, and own stock/stock options in, Flexion Therapeutics, Inc.
Role of the funding source Flexion Therapeutics, Inc., who funded this clinical trial, was involved in the study conception/design, data acquisition, and data analysis/interpretation. Authors currently or formerly employed by Flexion Therapeutics, Inc. (JL, JJ, JH, NB) drafted the article or revised it critically for important intellectual content; and approved the final submitted version.
